Squarepoint
CRVS icon

Squarepoint’s Corvus Pharmaceuticals CRVS Stock Holding History

Squarepoint’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$660K Sell
44,205
-79,691
-64% -$1.11M ﹤0.01% 3208
2026
Q1 		$1.81M Buy
123,896
+19,076
+18% +$304K ﹤0.01% 2250
2025
Q4 		$807K Buy
+104,820
New +$827K ﹤0.01% 2794
2025
Q3 		– Sell
-138,462
Closed -$554K – 4452
2025
Q2 		$554K Buy
138,462
+37,430
+37% +$136K ﹤0.01% 3187
2025
Q1 		$321K Buy
101,032
+2,888
+3% +$13.6K ﹤0.01% 3691
2024
Q4 		$525K Buy
98,144
+86,064
+712% +$642K ﹤0.01% 3688
2024
Q3 		$63.8K Buy
+12,080
New +$43.4K ﹤0.01% 3951
2023
Q3 		– Sell
-17,082
Closed -$39.1K – 3848
2023
Q2 		$39.1K Buy
+17,082
New +$35.5K ﹤0.01% 3459
2022
Q1 		– Sell
-13,118
Closed -$32K – 2936
2021
Q4 		$32K Sell
13,118
-6,836
-34% -$26.5K ﹤0.01% 3067
2021
Q3 		$97K Buy
+19,954
New +$59.1K ﹤0.01% 2674
2020
Q3 		– Sell
-26,418
Closed -$72K – 2534
2020
Q2 		$72K Buy
26,418
+1,982
+8% +$5.86K ﹤0.01% 2060
2020
Q1 		$52K Buy
+24,436
New +$99.2K ﹤0.01% 1715
2019
Q2 		– Sell
-45,785
Closed -$184K – 2412
2019
Q1 		$184K Sell
45,785
-27,669
-38% -$117K ﹤0.01% 1952
2018
Q4 		$270K Buy
73,454
+22,630
+45% +$154K ﹤0.01% 1550
2018
Q3 		$436K Buy
50,824
+35,771
+238% +$358K 0.01% 1363
2018
Q2 		$165K Buy
15,053
+1,675
+13% +$18.7K ﹤0.01% 1572
2018
Q1 		$154K Buy
+13,378
New +$127K ﹤0.01% 1530

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Squarepoint's CRVS Position: Q2 2026 in Review

Squarepoint reduced its Corvus Pharmaceuticals (CRVS) stake by 64% in Q2 2026, selling an estimated $1.11M and leaving 44,205 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #3208.

Squarepoint first reported a position in CRVS in Q1 2018 and has held it in 17 quarters since. The position peaked at $1.81M in Q1 2026. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Squarepoint held 44,205 shares of Corvus Pharmaceuticals worth $660K as of Q2 2026.
  • Squarepoint sold 79,691 Corvus Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3208 holding.
  • Squarepoint first reported a position in Corvus Pharmaceuticals in Q1 2018 and has held it in 17 quarters since.
  • Squarepoint's Corvus Pharmaceuticals position peaked at $1.81M in Q1 2026.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.